MX2013008225A - Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado. - Google Patents
Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado.Info
- Publication number
- MX2013008225A MX2013008225A MX2013008225A MX2013008225A MX2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- opioid agonist
- oxycodone
- compositions
- sequestered antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención pertenece a una composición farmacéutica que comprende una pluralidad de perlas multi-capa que tienen una capa de oxicodona y una subunidad secuestrante que comprende una naltrexona y un agente de bloqueo, en particular las composiciones farmacéuticas comprenden un mayor nivel de naltrexona, y composiciones y métodos de uso, tal como en la prevención del abuso de un agente terapéutico. Las composiciones de la presente invención poseen también un prolongado Tmax para liberación de oxicodona y un perfil de liberación de oxicodona más uniforme con el paso del tiempo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438882P | 2011-02-02 | 2011-02-02 | |
| PCT/IB2012/050348 WO2012104752A1 (en) | 2011-02-02 | 2012-01-25 | Pharmaceutical composition comprising opioid agonist and sequestered antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013008225A true MX2013008225A (es) | 2013-08-12 |
Family
ID=45607315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013008225A MX2013008225A (es) | 2011-02-02 | 2012-01-25 | Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140141090A1 (es) |
| EP (1) | EP2670400A1 (es) |
| JP (3) | JP2014504630A (es) |
| KR (4) | KR20130124551A (es) |
| CN (1) | CN103415285A (es) |
| AU (3) | AU2012213056A1 (es) |
| BR (1) | BR112013019431A2 (es) |
| CA (1) | CA2824835A1 (es) |
| IL (1) | IL227770A0 (es) |
| MX (1) | MX2013008225A (es) |
| RU (1) | RU2013136350A (es) |
| SG (1) | SG191872A1 (es) |
| WO (1) | WO2012104752A1 (es) |
| ZA (1) | ZA201305108B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL210845B1 (pl) | 2000-02-08 | 2012-03-30 | Euro Celtique Sa | Sposób wytwarzania doustnej postaci dawki |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| US20120076865A1 (en) | 2010-03-24 | 2012-03-29 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| IL311303A (en) * | 2017-10-09 | 2024-05-01 | Rhodes Pharmaceuticals Lp | Medicinal resin components and methods for their production and use |
| JP7472116B2 (ja) * | 2018-11-19 | 2024-04-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 耐アルコール性製剤 |
| JP7553453B2 (ja) | 2019-03-01 | 2024-09-18 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物 |
| KR20230071228A (ko) | 2021-11-16 | 2023-05-23 | 김명진 | 가상공간에 사용자가 마시는 주류를 적용하기 위한 방법 및 장치 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
| GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
| US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| PL210845B1 (pl) | 2000-02-08 | 2012-03-30 | Euro Celtique Sa | Sposób wytwarzania doustnej postaci dawki |
| CN2423892Y (zh) * | 2000-04-30 | 2001-03-21 | 尹为民 | 分隔式药物胶囊 |
| CN101439024A (zh) | 2001-05-11 | 2009-05-27 | 恩德制药公司 | 抗滥用阿片样物质剂型 |
| PL367427A1 (en) * | 2001-08-06 | 2005-02-21 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
| DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| US7226620B2 (en) | 2004-05-04 | 2007-06-05 | Rhodia Inc. | Directly compressible tricalcium phosphate |
| KR20140079441A (ko) | 2006-06-19 | 2014-06-26 | 알파마 파머슈티컬스 엘엘씨 | 약제학적 조성물 |
| EP2073797A2 (en) * | 2006-10-11 | 2009-07-01 | Alpharma, Inc. | Pharmaceutical compositions |
| US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| US20090196890A1 (en) * | 2007-12-17 | 2009-08-06 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
| CN101461809A (zh) * | 2007-12-18 | 2009-06-24 | 重庆药友制药有限责任公司 | 一种泮托拉唑钠肠溶片及其制备方法 |
| US20140030343A1 (en) * | 2010-10-26 | 2014-01-30 | Alpharma Pharmaceuticals Llc | Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose |
-
2012
- 2012-01-25 CA CA2824835A patent/CA2824835A1/en not_active Abandoned
- 2012-01-25 RU RU2013136350/15A patent/RU2013136350A/ru not_active Application Discontinuation
- 2012-01-25 KR KR1020137023085A patent/KR20130124551A/ko not_active Application Discontinuation
- 2012-01-25 MX MX2013008225A patent/MX2013008225A/es unknown
- 2012-01-25 KR KR1020187006298A patent/KR20180027641A/ko active Application Filing
- 2012-01-25 SG SG2013052188A patent/SG191872A1/en unknown
- 2012-01-25 JP JP2013552292A patent/JP2014504630A/ja not_active Withdrawn
- 2012-01-25 EP EP12704131.7A patent/EP2670400A1/en not_active Withdrawn
- 2012-01-25 KR KR1020167005412A patent/KR20160031038A/ko active Application Filing
- 2012-01-25 KR KR1020197002897A patent/KR20190014577A/ko not_active Application Discontinuation
- 2012-01-25 CN CN2012800076033A patent/CN103415285A/zh active Pending
- 2012-01-25 AU AU2012213056A patent/AU2012213056A1/en not_active Abandoned
- 2012-01-25 WO PCT/IB2012/050348 patent/WO2012104752A1/en active Application Filing
- 2012-01-25 BR BR112013019431-6A patent/BR112013019431A2/pt not_active IP Right Cessation
- 2012-01-25 US US13/982,890 patent/US20140141090A1/en not_active Abandoned
-
2013
- 2013-07-08 ZA ZA2013/05108A patent/ZA201305108B/en unknown
- 2013-08-01 IL IL227770A patent/IL227770A0/en unknown
-
2016
- 2016-02-04 AU AU2016200708A patent/AU2016200708A1/en not_active Abandoned
- 2016-12-07 JP JP2016237476A patent/JP2017081942A/ja not_active Withdrawn
-
2017
- 2017-07-07 AU AU2017204639A patent/AU2017204639A1/en not_active Abandoned
-
2018
- 2018-03-07 JP JP2018040441A patent/JP2018109059A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012104752A1 (en) | 2012-08-09 |
| JP2017081942A (ja) | 2017-05-18 |
| BR112013019431A2 (pt) | 2020-10-27 |
| JP2018109059A (ja) | 2018-07-12 |
| JP2014504630A (ja) | 2014-02-24 |
| KR20130124551A (ko) | 2013-11-14 |
| RU2013136350A (ru) | 2015-03-27 |
| EP2670400A1 (en) | 2013-12-11 |
| KR20160031038A (ko) | 2016-03-21 |
| ZA201305108B (en) | 2014-09-25 |
| US20140141090A1 (en) | 2014-05-22 |
| CA2824835A1 (en) | 2012-08-09 |
| AU2017204639A1 (en) | 2017-07-27 |
| CN103415285A (zh) | 2013-11-27 |
| IL227770A0 (en) | 2013-09-30 |
| KR20190014577A (ko) | 2019-02-12 |
| KR20180027641A (ko) | 2018-03-14 |
| AU2016200708A1 (en) | 2016-02-25 |
| AU2012213056A1 (en) | 2013-07-25 |
| SG191872A1 (en) | 2013-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013008225A (es) | Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado. | |
| HK1200741A1 (en) | Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist | |
| HK1201842A1 (en) | E-selectin antagonist compounds, compositions, and methods of use e- | |
| IL210185A0 (en) | Methods, compositions and systems for local delivery of drugs | |
| HK1193568A1 (en) | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence | |
| EP2680899A4 (en) | Medicament delivery device for administration of opioid antagonists including formulations for naloxone | |
| HK1187045A1 (en) | Buprenorphine analogs as opioid receptor agonists and or antagonists | |
| BRPI0919711A2 (pt) | composições farmacêuticas com liberação atenuada de opióides fenólicos | |
| WO2012032209A3 (es) | Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora. | |
| MX362838B (es) | Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente. | |
| MX348933B (es) | Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico. | |
| WO2009117669A3 (en) | Treatment with opioid antagonists and mtor inhibitors | |
| IL215813A0 (en) | Pariticulate pharmaceutical composition with an opioid and an opioid antagonist | |
| ZA201309359B (en) | Compositions for sequential administration of opioid receptor agonists | |
| MX2016008406A (es) | Preparacion farmaceutica combinada que comprende el bloqueante del receptor de la angiotensina ii y el inhibidor de la hmg-coa reductasa. | |
| IL233266A0 (en) | Methods for the treatment and prevention of opioid-induced constipation using oral compositions of methylnaltrexone | |
| PT2802311T (pt) | Composição farmacêutica sublingual contendo um agente anti-histamínico e método para a sua preparação | |
| AP2012006607A0 (en) | New combination between 4-ä3-ÄCIS-hexahydrocyclopenta[C]pyrrol-2(1H)-YL]propoxyübenzamide and an NMDA receptor antagonist and pharmaceutical compositions containing it | |
| EP2548893A4 (en) | DOUBLE ANTAGONIST FOR TNF-ALPHA AND IL-21 FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES | |
| TR201803744T4 (tr) | Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler. | |
| PH12017501767A1 (en) | Combination dosage form of a mu opioid receptor antagonist and an opioid agent | |
| ES1073779Y (es) | Barrera mixta, metal y madera, para carreteras. | |
| HK1203373A1 (en) | Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone | |
| GB201301179D0 (en) | Pharmaceutical composition comprising opioid analgesic | |
| TH1401003658A (th) | วิธีและองค์ประกอบทางเภสัชกรรมซึ่งปรับปรุงให้ดีขึ้นสำหรับเพิ่มการนำส่งสารยับยั้ง pde-5 ผ่านผิวหนัง |